Please login to the form below

Not currently logged in
Email:
Password:

Patients prefer AZ asthma drug

Details of a recent study presented at the International Conference of the American Thoracic Society in Toronto showed that asthma patients prefer AstraZeneca's (AZ) Symbicort to GlaxoSmithKline's (GSK) Adviar.

Details of a recent study presented at the International Conference of the American Thoracic Society in Toronto showed that asthma patients prefer AstraZeneca's (AZ) Symbicort to GlaxoSmithKline's (GSK) Adviar.

Patients involved in the open-label study favoured Symbicort administered as an adjustable dose treatment option as opposed to Advair. The two drugs have a similar mode of action and are competing against each other in the large and lucrative asthma market.

"These data showed that patients treated with Symbicort combination therapy fixed dose were more satisfied with the timelines of their symptom relief than those patients treated with Advair combination," said Dr Richard O'Connor, lead investigator of the study.

Despite being available as an adjustable dose treatment in over 87 countries, Symbicort is not indicated for that use in the US but was launched as a long-term maintenance treatment last year.

GSK reported global sales of Adviar worth $6.4bn in 2007 where as AZ recorded sales worth $1.6bn during the same year.

21st May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics